PE Tech Report


Like this article?

Sign up to our free newsletter

GI Partners to sell Generate Life Sciences to CooperCompanies

Private investment firm GI Partners is to sell Generate Life Sciences (Generate), a life sciences platform that provides reproductive and newborn stem cell (umbilical cord blood and tissue) services, to CooperCompanies (NYSE:COO).

Generate Life Sciences was created by GI Partners in 2018 as the combination of California Cryobank Life Sciences, an industry-leading donor sperm and egg bank, and Cord Blood Registry, a leading provider of newborn stem cell services. The combined business became a key player in three highly complementary end-markets. 

Generate serves families from preconception to post-birth throughout the significant and highly personalised journey of building a family and protecting their children’s health. Built upon the pillars of innovation, access, and connection, Generate has helped grow and protect nearly one million families globally.
Dave Kreter, Managing Director at GI Partners, says: “With the combination of these two leading companies we had a vision to create and build a platform that could address the personal desires of families’ reproductive and stem cell needs. Over the past three years we have focused our efforts and expertise to further Generate’s leadership and expand its suite of offerings. We would like to thank CEO Richard Jennings and his team for their partnership to build a leading life sciences company that serves customers in over 30 countries today.”
Richard Jennings, Chief Executive Officer of Generate, adds: “Generate helps families around the world benefit from an industry leading suite of reproductive, stem cell, and genetic services. Over the past several years, our company has transformed into a global organization supporting clients who want to create and protect healthy families. GI Partners has been instrumental in accelerating our growth in new markets and providing greater access to innovative science that promotes family wellness.”

Like this article? Sign up to our free newsletter